Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1288-1305

  Keravis, Thérèse ^a   Lugnier, Claire ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

cAMP; cGMP; cyclic nucleotide phosphodiesterases; distribution; expression; pathologies; PDE inhibitors; regulation; signalosome; therapeutic strategies

Indexed keywords

AMRINONE; CILOSTAMIDE; CILOSTAZOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ENOXIMONE; ENZYME INHIBITOR; MILRINONE; ND 7001; NIMODIPINE; OXINDOLE; PAPAVERINE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IX; PHOSPHODIESTERASE V; PHOSPHODIESTERASE VI; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VIII; PHOSPHODIESTERASE X; PHOSPHODIESTERASE XI; ROLIPRAM; SILDENAFIL; SPLEEN EXONUCLEASE; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VINPOCETINE; ZAPRINAST;

ACUTE LUNG INJURY; CALCIUM SIGNALING; CELL CYCLE REGULATION; CELL INTERACTION; CELL PROLIFERATION; DIMERIZATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME SPECIFICITY; ERECTILE DYSFUNCTION; GLUCOSE TRANSPORT; HEART VENTRICLE HYPERTROPHY; HUMAN; HYDROLYSIS; HYDROPHOBICITY; IC 50; LIPOGENESIS; LIPOLYSIS; MOLECULAR DYNAMICS; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; HUMANS; ISOENZYMES; NUCLEOTIDES, CYCLIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION;

EID: 84857080656     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01729.x     Document Type: Review

References (221)

1. Abusnina A, Alhosin M, Keravis T, Muller CD, Fuhrmann G, Bronner C, et al,. (2011). Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cell Signal 23: 152-160.
2. Ahmad F, Lindh R, Tang Y, Ruishalme I, Ost A, Sahachartsiri B, et al,. (2009). Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3-adrenergic receptor agonist CL316243: effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes. Biochem J 424: 399-410.
3. Ahn HS, Foster M, Foster C, Sybertz E, Wells JN, (1989). Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 38: 3331-3339.
4. Ahn HS, Bercovici A, Boykow G, Bronnenkant A, Chackalamannil S, Chow J, et al,. (1997). Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. J Med Chem 40: 2196-2210.
5. Alhosin M, Abusnina A, Achour M, Sharif T, Muller C, Peluso J, et al,. (2010). Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol 79: 1251-1260.
6. Amer MS, (1977). Cyclic nucleotides as targets for drug design. Adv Drug Res 12: 1-38.
7. Anant JS, Ong OC, Xie HY, Clarke S, O'Brien PJ, Fung BK, (1992). In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits. J Biol Chem 267: 687-690.
8. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, et al,. (2011). Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19: 45-57.
9. Artemyev NO, Surendran R, Lee JC, Hamm HE, (1996). Subunit structure of rod cGMP-phosphodiesterase. J Biol Chem 271: 25382-25388.
10. Aspiotis R, Deschênes D, Dubé D, Girard Y, Huang Z, Laliberté F, et al,. (2010). The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett 20: 5502-5505.
11. Assad-Kottner C, Chen D, Jahanyar J, Cordova F, Summers N, Loebe M, et al,. (2008). The use of continuous milrinone therapy as bridge to transplant is safe in patients with short waiting times. J Card Fail 14: 839-843.
12. Auerbach R, Kubai L, Knighton D, Folkman J, (1974). A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 41: 391-394.
13. Baillie GS, MacKenzie SJ, McPhee I, Houslay MD, (2000). Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br J Pharmacol 131: 811-819.
14. 2+- triggered membrane association with selectivity for interaction with phosphatidic acid. J Biol Chem 277: 28298-28309.
15. Banner KH, Press NJ, (2009). Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 157: 892-906.
16. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, et al,. (2004). Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 287: L332-L343.
17. Bates MG, Thompson AA, Baillie JK, (2007). Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema. Curr Opin Investig Drugs 8: 226-231.
18. Beard MB, Olsen AE, Jones RE, Erdogan S, Houslay MD, Bolger GB, (2000). UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J Biol Chem 275: 10349-10358.
19. Beavo JA, (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725-748.
20. Beavo JA, Brunton LL, (2002). Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol 3: 710-718.
21. Beavo JA, Francis SH, Houslay MD, (eds) (2006). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, USA.
22. Bender AT, (2006). Calmodulin-stimulated cyclic nucleotide phosphodiesterases. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 35-54.
23. Bender AT, Beavo JA, (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
24. Berger K, Lindh R, Wierup N, Zmuda-Trzebiatowska E, Lindqvist A, Manganiello VC, et al,. (2009). Phosphodiesterase 3B is localized in caveolae and smooth ER in mouse hepatocytes and is important in the regulation of glucose and lipid metabolism. PLoS ONE 4: e4671.
25. Biel M, Michalakis S, (2009). Cyclic nucleotide-gated channels. Handb Exp Pharmacol 191: 111-136.
26. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, et al,. (2004). Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47: 1081-1092.
27. Boichot E, Wallace JL, Germain N, Corbel M, Lugnier C, Lagente V, et al,. (2000). Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine. J Pharmacol Exp Ther 292: 647-653.
28. Bolger GB, (2006). Phosphodiesterase isoforms-an annoted list. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 19-31.
29. Bolger G, Michaeli T, Martins T, St John T, Steiner B, Rodgers L, et al,. (1993). A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol 13: 6558-6571.
30. Borisy FF, Ronnett GV, Cunningham AM, Juilfs D, Beavo J, Synder SH, (1992). Calcium/calmodulin-activated phosphodiesterase expressed in olfactory receptor neurons. J Neurosci 12: 915-923.
31. Borland G, Smith BO, Yarwood SJ, (2009). EPAC proteins transduce diverse cellular actions of cAMP. Br J Pharmacol 158: 70-86.
32. Boswell-Smith V, Spina D, Page CP, (2006). Phosphodiesterase inhibitors. Br J Pharmacol 147: S252-S257.
33. Bourguignon JJ, Lugnier C, Abarghaz M, Lagouge Y, Wagner P, Mondadori C, et al,. (2004). Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses. Patent WO2004041258, published 21.05.2004. International Application N°: PCT/FR2003/003247 (30.10.2003).
34. Burgin AB, Olafur T, Magnusson OT, Singh J, Witte P, Bart L, et al,. (2010). Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28: 63-70.
35. Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C, (2008). Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells. Br J Pharmacol 154: 82-92.
36. Castaño T, Wang H, Campillo NE, Ballester S, González- García C, Hernández J, et al,. (2009). Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors. ChemMedChem 4: 866-876.
37. Casteel DE, Smith-Nguyen EV, Sankaran B, Roh SH, Pilz RB, Kim C, (2010). A crystal structure of the cyclic GMP-dependent protein kinase Iβ dimerization/docking domain reveals molecular details of isoform-specific anchoring. J Biol Chem 285: 32684-32688.
38. Chambers RJ, Abrams K, Garceau NY, Kamath AV, Manley CM, Lilley SC, et al,. (2006). A new chemical tool for exploring the physiological function of the PDE2 isozyme. Bioorg Med Chem Lett 16: 307-310.
39. Cho ES, Yu JH, Kim MS, Yim M, (2005). Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts. Yonsei Med J 46: 149-154.
40. Conti M, Beavo J, (2007). Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481-511.
41. Cote RH, (2006). Photoreceptor phosphodiesterase (PDE6): a G-protein-activated PDE regulating visual excitation in rod and cone photoreceptor cells. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 165-193.
42. Croom KF, Curran MP, (2008). Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 68: 383-397.
43. Cukkemane A, Seifert R, Kaupp UB, (2011). Cooperative and uncooperative cyclic-nucleotide-gated ion channels. Trends Biochem Sci 36: 55-64.
44. Daugan A, Grondin P, Ruault C, Le Monnier de Gouville AC, Coste H, Kirilovsky J, et al,. (2003). The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1′,5′: 1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues. J Med Chem 46: 4525-4532.
45. Day JP, Lindsay B, Riddell T, Jiang Z, Allcock RW, Abraham A, et al,. (2011). Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4). J Med Chem 54: 3331-3347.
46. Degerman E, Manganiello V, (2006). Phosphodiesterase 3B: an important regulator of energy homeostasis. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 79-97.
47. Dell'Acqua ML, Scott JD, (1997). Protein kinase A anchoring. J Biol Chem 272: 12881-12884.
48. Demirbas D, Ceyhan O, Wyman AR, Ivey FD, Allain C, Wang L, et al,. (2011). Use of a Schizosaccharomyces pombe PKA-repressible reporter to study cGMP metabolising phosphodiesterases. Cell Signal 23: 594-601.
49. DeNinno MP, Andrews M, Bell AS, Chen Y, Eller-Zarbo C, Eshelby N, (2009). The discovery of potent, selective and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. Bioorg Med Chem Lett 19: 2537-2541.
50. Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, et al,. (2001). mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 20: 1921-1930.
51. Domek-Śopacińska KU, Strosznajder JB, (2010). Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol Neurobiol 41: 129-137.
52. Duncan GS, Wolberg G, Schmitges CJ, Deeprose RD, Zimmerman TP, (1982). Inhibition of lymphocyte-mediated cytolysis and cyclic AMP phosphodiesterase by erythro-9-(2-hydroxy-3-nonyl)adenine. J Immunopharmacol 4: 79-100.
53. Eckly AE, Lugnier C, (1994). role of phosphodiesterase-III and phosphodiesterase-IV in the modulation of vascular cyclic-AMP content by the NO/cyclic-GMP pathway. Br J Pharmacol 113: 445-450.
54. Eckly-Michel A, Martin V, Lugnier C, (1997). Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation. Br J Pharmacol 122: 158-164.
55. Favot L, Keravis T, Holl V, Le Bec A, Lugnier C, (2003). VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost 90: 334-343.
56. Favot L, Keravis T, Lugnier C, (2004). Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost 92: 634-645.
57. Fisher DA, Smith JF, Pillar JS, St. Denis SH, Cheng JB, (1998). Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273: 15559-15564.
58. Forte LR, Thorne PK, Eber SL, Krause WJ, Freeman RH, Francis SH, et al,. (1992). Stimulation of intestinal Cl-transport by heat-stable enterotoxin: activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 263: C607-C615.
59. Francis SH, Corbin JD, (1999). Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36: 275-328.
60. Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blount MA, et al,. (2006). Phosphodiesterase 5: molecular characteristics relating to structure function and regulation. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 131-164.
61. Francis SH, Morris GZ, Corbin JD, (2008). Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. Int J Impot Res 20: 333-342.
62. Francis SH, Corbin JD, Bischoff E, (2009). Cyclic GMP-hydrolyzing phosphodiesterases. Handb Exp Pharmacol 191: 367-408.
63. Francis SH, Blount MA, Corbin JD, (2011). Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91: 651-690.
64. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, et al,. (1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274: 18438-18445.
65. Fujishige K, Kotera J, Yuasa K, Omori K, (2000). The human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domains. Eur J Biochem 267: 5943-5951.
66. Gamanuma M, Yuasa K, Sasaki T, Sakurai N, Kotera J, Omori K, (2003). Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. Cell Signal 15: 565-574.
67. Gebska MA, Stevenson BK, Hemnes AR, Bivalacqua TJ, Haile A, Hesketh GG, et al,. (2011). Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity. Cardiovasc Res 90: 353-363.
68. Geoffroy V, Fouque F, Nivet V, Clot JP, Lugnier C, Desbuquois B, et al,. (1999). Activation of a cGMP-stimulated cAMP phosphodiesterase by protein kinase C in a liver Golgi-endosomal fraction. Eur J Biochem 259: 892-900.
69. Geoffroy V, Fouque F, Lugnier C, Desbuquois B, Benelli C, (2001). Characterization of an in vivo hormonally regulated phosphodiesterase 3 (PDE3) associated with a liver Golgi-endosomal fraction. Arch Biochem Biophys 387: 154-162.
70. Gesellchen F, Zaccolo M, (2011). Phosphodiesterase 2A, cGMP stimulated. UCSD Nat Mol. DOI: 10.1038/mp.a001750.01.
71. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al,. (2002). Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360: 895-900.
72. Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR, (2010). Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS ONE 5: e13417.
73. Giorgi M, Melchiorri G, Nuccetelli V, D'Angelo V, Martorana A, Sorge R, et al,. (2011). PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in Parkinsonism physiopathology. Neurobiol Dis 43: 293-303.
74. Gloerich M, Bos JL, (2010). Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 50: 355-375.
75. Gonçalves RL, Lugnier C, Keravis T, Lopes MJ, Fantini FA, Schmitt M, et al,. (2009). The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. Eur J Pharmacol 620: 78-83.
76. Grandoch M, Roscioni SS, Schmidt M, (2010). The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol 159: 265-284.
77. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, et al,. (2009). Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331: 574-590.
78. Guazzi M, Vicenzi M, Arena R, Guazzi MD, (2011). PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4: 8-17.
79. Hanson MS, Stephenson AH, Bowles EA, Sprague RS, (2010). Insulin inhibits human erythrocyte cAMP accumulation and ATP release: role of phosphodiesterase 3 and phosphoinositide 3-kinase. Exp Biol Med 235: 256-262.
80. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al,. (2010). The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23: 235-256.
81. Hayashi M, Shimada Y, Nishimura Y, Hama T, Tanaka T, (2002). Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene. Biochem Biophys Res Commun 297: 1253-1258.
82. Heikaus CC, Pandit J, Klevit RE, (2009). Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights. Structure 17: 1551-1557.
83. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, et al,. (1979). Selective inhibitor of platelet cyclic adenosine mono- phosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 211: 26-30.
84. Houslay MD, (2010). Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35: 91-100.
85. Houslay MD, (2011). Hard times for oncogenic BRAF-expressing melanoma cells. Cancer Cell 19: 3-4.
86. Houslay MD, Adams DR, (2003). PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370: 1-18.
87. Houslay MD, Schafer P, Zhang KY, (2005). Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10: 1503-1519.
88. Huston E, Gall I, Houslay TM, Houslay MD, (2006). Helix-1 of the cAMP-specific phosphodiesterase PDE4A1 regulates its phospholipase-D-dependent redistribution in response to release of Ca 2+. J Cell Sci 119: 3799-3810.
89. Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE, et al,. (2011). The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl] -1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 61: 665-676.
90. Insel PA, Zhang L, Murray F, Yokouchi H, Zambon AC, (2011). Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf). DOI: 10.1111/j.1748-1716.2011.02273 [Epub ahead of print].
91. Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, et al,. (2010). Vinpocetine inhibits NF-kB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci U S A 107: 9795-9800.
92. Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, et al,. (2009). ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced IFN-gamma production by mouse activated T lymphocytes. Immunol Lett 122: 193-197.
93. Kakkar R, Raju RV, Sharma RK, (1999). Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1). Cell Mol Life Sci 55: 1164-1186.
94. Kameni-Tcheudji JF, Lebeau L, Virmaux N, Maftei CG, Cote RH, Lugnier C, et al,. (2001). Molecular organization of bovine rod cGMP- phosphodiesterase 6. J Mol Biol 310: 781-791.
95. Kass DA, Champion HC, Beavo JA, (2007). Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101: 1084-1095.
96. Kaupp UB, Seifert R, (2002). Cyclic nucleotide-gated ion channels. Physiol Rev 82: 769-824.
97. Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, et al,. (2010). Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease related phenotypes. Proc Natl Acad Sci USA 107: 8457-8462.
98. Keravis T, Lugnier C, (2010). Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs. Curr Pharm Des 16: 1114-1125.
99. Keravis T, Silva AP, Favot L, Lugnier C, (2006). Role of PDEs in vascular health and disease: endothelial PDEs and angiogenesis. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 417-439.
100. Keravis T, Vandecasteele G, Mokni W, Fischmeister R, Lugnier C, (2007). Identification of PDE1 and PDE5 in adult rat left ventricles cardiomyocytes. J Mol Cell Cardiol 42: S49-S50.
101. Kim DH, Lerner A, (1998). Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 92: 2484-2494.
102. Komas N, Lugnier C, Le Bec A, Serradeil-Le Gal C, Barthelemy G, Stoclet JC, (1989). Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues. J Cardiovasc Pharmacol 14: 213-220.
103. Komas N, Lugnier C, Stoclet JC, (1991). Endothelium-dependent and independent relaxation of the rat aorta by cyclic-nucleotide phosphodiesterase inhibitors. Br J Pharmacol 104: 495-503.
104. Kumar P, Francis GS, Tang WH, (2009). Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nat Rev Cardiol 6: 349-355.
105. Lamas M, Sassone-Corsi P, (1997). The dynamics of the transcriptional response to cyclic adenosine 3,5-monophosphate: recurrent inducibility and refractory phase. Mol Endocrinol 11: 1415-1424.
106. Lanfear DE, Hasan R, Gupta RC, Williams C, Czerska B, Tita C, et al,. (2009). Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure. J Transl Med 7: 67. DOI: 10.1186/1479-5876-7-67.
107. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A, (2002). PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal 14: 277-284.
108. Lerner A, Kim DH, Lee R, (2000). The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma 37: 39-51.
109. Libé R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, et al,. (2011). Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab 96: E208-E214.
110. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, et al,. (2010). Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 121: 1474-1483.
111. Lugnier C, (ed.) (2005). Phosphodiesterase Methods and Protocols, Methods in Molecular Biology 307. Humana Press: Totowa.
112. Lugnier C, (2006). Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398.
113. Lugnier C, Schini VB, (1990). Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem Pharmacol 39: 75-84.
114. Lugnier C, Stierlé A, Beretz A, Schoeffter P, Le Bec A, Wermuth CG, et al,. (1983). Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases: relationship to pharmacological activity. Biochem Biophys Res Commun 113: 954-959.
115. Lugnier C, Follénius A, Gérard D, Stoclet JC, (1984). Bepridil and flunarizine as calmodulin inhibitors. Eur J Pharmacol 98: 157-158.
116. Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC, (1986). Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35: 1743-1751.
117. Lugnier C, Muller B, Le Bec A, Beaudry C, Rousseau E, (1993). Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 265: 1142-1151.
118. Lugnier C, Keravis T, Le Bec A, Pauvert O, Proteau S, Rousseau E, (1999). Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1472: 431-446.
119. Makhlouf A, Kshirsagar A, Niederberger C, (2006). Phosphodiesterase 11: a brief review of structure, expression and function. Int J Impot Res 18: 501-509.
120. Manneville JB, Jehanno M, Etienne-Manneville S, (2010). Dlg1 binds GKAP to control dynein association with microtubules, centrosome positioning, and cell polarity. J Cell Biol 191: 585-598.
121. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, et al,. (1999). Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 128: 1393-1398.
122. Marivet MC, Bourguignon JJ, Lugnier C, Mann A, Stoclet JC, Wermuth CG, (1989). Inhibition of cyclic adenosine-3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J Med Chem 32: 1450-1457.
123. Martinez SE, (2006). PDE2 structure and functions. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 55-77.
124. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, et al,. (2002). The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci USA 99: 13260-13265.
125. Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, et al,. (2009). Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther 331: 690-699.
126. Matulef K, Zagotta WN, (2003). Cyclic nucleotide-gated ion channels. Annu Rev Cell Dev Biol 19: 23-44.
127. Maurice DH, Haslam RJ, (1990). Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37: 671-681.
128. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, et al,. (2005). In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal 17: 1158-1173.
129. Mentz F, Merle-Beral H, Ouaaz F, Binet JL, (1995). Theophylline, a new inducer of apoptosis in B-CLL: role of cyclic nucleotides. Br J Haematol 90: 957-959.
130. Meyers JA, Su DW, Lerner A, (2009). Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J Immunol 182: 5400-5411.
131. Michaeli T, (2006). PDE7. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 195-203.
132. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S, (2002). Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105: 2398-2403.
133. Miki N, Baraban JM, Keirns JJ, Boyce JJ, Bitensky MW, (1975). Purification and properties of the light-activated cyclic nucleotide phosphodiesterase of rod outer segments. J Biol Chem 250: 6320-6327.
134. Miller CL, Oikawa M, Cai Y, Wojtovich AP, Nagel DJ, Xu X, et al,. (2009). Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 105: 956-964.
135. Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane MO, Schini-Kerth VB, et al,. (2010). Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II. PLoS ONE 5: e14227.
136. Moorthy BS, Gao Y, Anand GS, (2011). Phosphodiesterases catalyze hydrolysis of cAMP bound to regulatory subunit of protein kinase A and mediate signal termination. Mol Cell Proteomics 10: M110.002295.
137. Morin F, Lugnier C, Kameni J, Voisin P, (2001). Expression and role of phosphodiesterase 6 in the chicken pineal gland. J Neurochem 78: 88-99.
138. Movsesian MA, Kukreja RC, (2011). Phosphodiesterase inhibition in heart failure. Handb Exp Pharmacol 204: 237-249.
139. Movsesian MA, Smith CJ, (2006). Role of cyclic nucleotides phosphodiesterases in heart failure and hypertension. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 485-500.
140. Murray F, MacLean MR, Pyne NJ, (2003). An assessment of the role of the inhibitory gamma subunit of the retinal cyclic GMP phosphodiesterase and its effect on the p42/p44 mitogen-activated protein kinase pathway in animal and cellular models of pulmonary hypertension. Br J Pharmacol 138: 1313-1319.
141. Murray F, Patel HH, Suda RY, Zhang S, Thistlethwaite PA, Yuan JX, et al,. (2007). Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am J Physiol Lung Cell Mol Physiol 292: L294-L303.
142. 2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival. Circ Res 98: 777-784.
143. Netherton SJ, Maurice DH, (2005). Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol 67: 263-272.
144. Nikolova S, Guenther A, Savai R, Weissmann N, Ghofrani HA, Konigshoff M, et al,. (2010). Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. Respir Res 11: 146.
145. Nilsson R, Ahmad F, Swärd K, Andersson U, Weston M, Manganiello V, et al,. (2006). Plasma membrane cyclic nucleotide phosphodiesterase 3B (PDE3B) is associated with caveolae in primary adipocytes. Cell Signal 18: 1713-1721.
146. 2+ sources. Naunyn Schmiedebergs Arch Pharmacol 363: 612-619.
147. Omori K, Kotera J, (2006). PDE11. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health Disease. CRC Press: Boca Raton, pp. 255-274.
148. Omori K, Kotera J, (2007). Overview of PDEs and their regulation. Circ Res 100: 309-327.
149. Pagès L, Gavaldà A, Lehner MD, (2009). PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin Ther Pat 19: 1501-1519.
150. Palmer D, Jimmo SL, Raymond DR, Wilson LS, Carter RL, Maurice DH, (2007). Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation. J Biol Chem 282: 9411-9419.
151. Pande RL, Hiatt WR, Zhang P, Hittel N, Creager MA, McDermott M, (2010). A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 15: 181-188.
152. Pang DC, (1988). Cyclic AMP and cyclic GMP phosphodiesterases: target for drug development. Drug Dev Res 12: 85-92.
153. Patrucco E, Albergine MS, Santana LF, Beavo JA, (2010). Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. J Mol Cell Cardiol 49: 330-333.
154. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, Baillie GS, et al,. (2011). Integrating cardiac PIP(3) and cAMP signaling through a PKA anchoring function of p110γ. Mol Cell 42: 84-95.
155. Podzuweit T, Nennstiel P, Müller A, (1995). Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 7: 733-738.
156. Pozuelo Rubio M, Campbell DG, Morrice NA, Mackintosh C, (2005). Phosphodiesterase 3A binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem J 392: 163-172.
157. Puzzo D, Sapienza S, Arancio O, Palmeri A, (2008). Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 4: 371-387.
158. Rampersad SN, Ovens JD, Huston E, Umana MB, Wilson LS, Netherton SJ, et al,. (2010). Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability. J Biol Chem 285: 33614-33622.
159. Ranpura V, Hapani S, Wu S, (2011). Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487-494.
160. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J, (2009). Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 202: 419-443.
161. Rentero C, Monfort A, Puigdomènech P, (2003). Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun 301: 686-692.
162. Rentsendorj O, Damarla M, Aggarwal NR, Choi JY, Johnston L, D'Alessio FR, et al,. (2011). Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 301: L161-L170.
163. Richter W, Conti M, (2004). The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases. J Biol Chem 279: 30338-30348.
164. Ridge KD, Abdulaev NG, Sousa M, Palczewski K, (2003). Phototransduction: crystal clear. Trends Biochem Sci 28: 479-487.
165. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, et al,. (1998). Epac is a Rap1 guanine- nucleotide-exchange factor directly activated by cyclic AMP. Nature 396: 474-477.
166. Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE, (2002). Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90: 151-157.
167. Saenz de Tejada I, Argulo Frutos J, Gadau M, Florio V, (2002). Comparative selectivity profiles of tadalafil, sildenafil and vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res 14: S20.
168. Sasaki T, Kotera J, Omori K, (2004). Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/ cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 89: 474-483.
169. Schaeffer HJ, Schwender CF, (1974). Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines. J Med Chem 17: 6-8.
170. Schermuly RT, Pullamsetti SS, Kwapiszewska G, Dumitrascu R, Tian X, Weissmann N, et al,. (2007). Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115: 2331-2339.
171. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, et al,. (2008). Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325: 681-690.
172. Schneider HH, Schmiechen R, Brezinski M, Seidler J, (1986). Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127: 105-115.
173. Schultz JE, (2009). Structural and biochemical aspects of tandem GAF domains. Handb Exp Pharmacol 191: 93-109.
174. Schwabe U, Miyake M, Ohga Y, Daly JW, (1976). 4-(3-Cyclopentyloxy-4- methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′,5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain. Mol Pharmacol 12: 900-910.
175. Scotland G, Houslay MD, (1995). Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase. Biochem J 308: 673-681.
176. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Bürger A, et al,. (2005). Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105: 3569-3576.
177. Sharma RK, Das SB, Lakshmikuttyamma A, Selvakumar P, Shrivastav A, (2006). Regulation of calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1): review. Int J Mol Med 18: 95-105.
178. Sin YY, Edwards HV, Li X, Day JP, Christian F, Dunlop AJ, et al,. (2011). Disruption of the cyclic AMP phosphodiesterase-4 (PDE4)-HSP20 complex attenuates the β-agonist induced hypertrophic response in cardiac myocytes. J Mol Cell Cardiol 50: 872-883.
179. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, et al,. (2006). Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51: 386-396.
180. Skroblin P, Grossmann S, Schäfer G, Rosenthal W, Klussmann E, (2010). Mechanisms of protein kinase A anchoring. Int Rev. Cell Mol Biol 283: 235-330.
181. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, et al,. (2004). Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl- nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66: 1679-1689.
182. Snyder PB, Esselstyn JM, Loughney K, Wolda SL, Florio VA, (2005). The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J Lipid Res 46: 494-503.
183. Souness JE, Diocee BK, Martin W, Moodie SA, (1990). Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells. Biochem J 266: 127-132.
184. Spina D, (2008). PDE4 inhibitors: current status. Br J Pharmacol 155: 308-315.
185. van der Staay FJ, Rutten K, Bärfacker L, Devry J, Erb C, Heckroth H, et al,. (2008). The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 55: 908-918.
186. Stoclet JC, Boulanger-Saunier C, Lassegue B, Lugnier C, (1988). Cyclic nucleotides and calcium regulation in heart and smooth muscle cells. Ann NY Acad Sci 522: 106-115.
187. Strick CA, Schmidt CJ, Menneti FS, (2006). PDE10A: a striatum-enriched, dual-substrate phosphodiesterase. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 237-254.
188. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, et al,. (2005). cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96: 100-109.
189. Tate RJ, Arshavsky VY, Pyne NJ, (2002). The identification of the inhibitory gamma-subunits of the type 6 retinal cyclic guanosine monophosphate phosphodiesterase in non-retinal tissues: differential processing of mRNA transcripts. Genomics 79: 582-586.
190. Tian X, Vroom C, Ghofrani HA, Weissmann N, Bieniek E, Grimminger F, et al,. (2011). Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. PLoS ONE 6: e18136. DOI: 10.1371/journal.pone.0018136.
191. Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, et al,. (2009). Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009: 3331-3340.
192. Tiwari S, Dong H, Kim EJ, Weintraub L, Epstein PM, Lerner A, (2005). Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol 69: 473-483.
193. Tsai EJ, Kass DA, (2009). Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 122: 216-238.
194. Tsai LC, Shimizu-Albergine M, Beavo JA, (2011). The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. Mol Pharmacol 79: 639-648.
195. Turko IV, Francis SH, Corbin JD, (1998). Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J 329: 505-510.
196. Vandeput F, Wolda SL, Krall J, Hambleton R, Uher L, McCaw KN, et al,. (2007). Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem 282: 32749-32757.
197. Vang AG, Ben-Sasson SZ, Dong H, Kream B, DeNinno MP, Claffey MM, et al,. (2010). PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. PLoS ONE 5: e12011.
198. Vasta V, (2006). cAMP-phosphodiesterase 8 family. In:, Beavo JA, Francis SH, Houslay MD, (eds). Cyclic Nucleotide Phosphodiesterases in Health and Disease. CRC Press: Boca Raton, pp. 205-219.
199. Vecsey CG, Baillie GS, Jaganath D, Havekes R, Daniels A, Wimmer M, et al,. (2009). Sleep deprivation impairs cAMP signaling in the hippocampus. Nature 461: 1122-1125.
200. Vergne F, Bernardelli P, Lorthiois E, Pham N, Proust E, Oliveira C, et al,. (2004). Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors: Part 2. Metabolism-directed optimization studies towards orally bioavailable derivatives. Bioorg Med Chem Lett 14: 4615-4621.
201. Vo NK, Gettemy JM, Coghlan VM, (1998). Identification of cGMP-dependent protein kinase anchoring proteins (GKAPs). Biochem Biophys Res Commun 246: 831-835.
202. Wallis RM, Corbin JD, Francis SH, Ellis P, (1999). Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83: 3C-12C.
203. Wan KF, Sambi BS, Frame M, Tate R, Pyne NJ, (2001). The inhibitory gamma subunit of the type 6 retinal cyclic guanosine monophosphate phosphodiesterase is a novel intermediate regulating p42/p44 mitogen-activated protein kinase signaling in human embryonic kidney 293 cells. J Biol Chem 276: 37802-37808.
204. Wang H, Robinson H, Ke H, (2010). Conformation Changes, N-terminal Involvement, and cGMP Signal Relay in the Phosphodiesterase-5 GAF Domain. J Biol Chem 285: 38149-38156.
205. Wang P, Wu P, Egan RW, Billah MM, (2001). Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. Gene 280: 183-194.
206. Wang P, Wu P, Egan RW, Billah MM, (2003). Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants. Gene 314: 15-27.
207. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, Movsesian MA, (2002). Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 277: 38072-38078.
208. Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, Corbin JD, (2005). High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 17: 5-9.
209. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR, (1987). Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 61: 539-547.
210. Welch EJ, Jones BW, Scott JD, (2010). Networking with AKAPs: context-dependent regulation of anchored enzymes. Mol Interv 10: 86-97.
211. Wensel TG, (2008). Signal transducing membrane complexes of photoreceptor outer segments. Vision Res 48: 2052-2061.
212. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B, et al,. (2001). Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104: 1218-1222.
213. Wilson LS, Baillie GS, Pritchard LM, Umana B, Terrin A, Zaccolo M, et al,. (2011). A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP and phosphatidylinositol 3-kinase signals in human arterial endothelial cells. J Biol Chem 286: 16285-16296.
214. Wong W, Scott JD, (2004). AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 5: 959-970.
215. Wu SN, Li HF, Chiang HT, (2001). Vinpocetine-induced stimulation of calcium-activated potassium currents in rat pituitary GH3 cells. Biochem Pharmacol 61: 877-892.
216. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M, (2005). Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68: 1775-1781.
217. Wunder F, Gnoth MJ, Geerts A, Barufe D, (2009). A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors. Mol Pharmacol 6: 326-336.
218. Yan C, Zhao AZ, Bentley JK, Beavo JA, (1996). The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem 271: 25699-25706.
219. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K, (2000). Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 275: 31469-31479.
220. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, et al,. (2008). Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 105: 19532-19537.
221. Zmuda-Trzebiatowska E, Oknianska A, Manganiello V, Degerman E, (2006). Role of PDE3B in insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis in primary rat adipocytes. Cell Signal 18: 382-390.